CoronavirusCovid-19Health

New COVID Drug Tested in DMV Shows Promise: Study

A new drug designed to treat severe COVID-19 cases is being tested in the D.C. region and has shown promise, researchers say.

The drug, Fostamantinib, is a product of pharmaceutical company Rigel, WTTG-TV (Channel 5) reported. Inova is partnering with the National Institutes of Health to direct phase 2 of research.

The study was conducted on 59 participants, WTTG reported. Early results showed patients treated with Fostamantinib had less harsh effects from the coronavirus and better clinical outcomes.

“We are particularly excited about some of this efficacy data coming out of this study,” said Dr. Steven Nathan, medical director of Inova’s advanced lung disease and lung transplant program, WTTG reported. “It looked like the patients spent less time in the ICU, less time in the hospital.”

Nathan said patients spent less time on oxygen and had lower mortality rates. The three deaths in the study had received a placebo, he said.

Despite the promising developments, Nathan said Fostamatinib is still in the early research stages. Phase-three testing is being conducted in South America and, pending those results, Rigel will submit the drug to the Food and Drug Administration for approval, WTTG reported.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Adblock Detected

Please consider supporting us by disabling your ad blocker